University of Hyderabad-based start-up to combat antimicrobial resistance
The partnership strengthens the ties between UK and India while addressing one of the most urgent global health challenges—antimicrobial resistance (AMR)
Hyderabad: Microbira Limited, a UK-based biotech company, and Hyderabad-based SCIINV Biosciences, incubated at ASPIRE BioNEST in University of Hyderabad (UoH) announced the launch of joint venture to combat antimicrobial resistance with an initial investment of £1 million.
The partnership strengthens the ties between UK and India while addressing one of the most urgent global health challenges—antimicrobial resistance (AMR).
Sharing his enthusiasm for the collaboration, British Deputy High Commissioner to Telangana and Andhra Pradesh, Gareth Wynn Owen said the joint venture was a fantastic step forward in the fight against AMR.
“It’s wonderful to see the UK-India innovation pipeline in action. We are excited to see the impact this will have in both countries and beyond,” Owen said.
The joint venture is driven by a common vision: effective and rapid identification of microorganisms is critical for controlling the spread of drug-resistant infections.
By developing a fast, accurate, and affordable identification platform, the partners aim to reduce the misuse of broad-spectrum antibiotics—a key contributor to AMR, particularly in India.
“At SCIINV Biosciences, we believe that technological innovation can transform healthcare, and this partnership will allow us to offer solutions that are not only advanced but also accessible and impactful,” said Dr. P. Ratnakar, Co-founder and Director of SCIINV Biosciences.
Microbira Ltd CEO Marianne Ismail said the collaboration with SCIINV Biosciences was more than just a business agreement. “It’s about leveraging our collective expertise to develop solutions that meet the rigorous regulatory standards of both India and the global market,” Ismail added.
